Is Clinical Remission, an Ambitious Treatment Goal, Achievable in Patients with Moderate-to-Severe Asthma on Inhaled Therapies: How Ambitious Should We Be?
Open Access
- 14 February 2026
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1497
Abstract
Background/Objectives: Clinical remission (CR) is an ambitious and attainable treatment goal for asthma; however, CR definitions vary. Evidence of CR in Japanese patients with moderate-to-severe asthma on inhaled therapies is lacking and was evaluated based on three guideline definitions: the United States Workgroup consensus statement, Japanese Guidelines for adult asthma (JGL), and Practical Guidelines for Asthma Management (PGAM). Methods: Post hoc analysis of Phase III studies including Japanese participants: Japanese subpopulation of CAPTAIN (NCT02924688) and a 52-week Japanese long-term safety study (NCT03184987). CAPTAIN randomized participants to once-daily fluticasone furoate/vilanterol (FF/VI) regimens ± umeclidinium (UMEC). The long-term safety study allocated participants to once-daily FF/UMEC/VI based on asthma control status. All three CR definitions assessed systemic corticosteroid use, severe exacerbations, and asthma control (Asthma Control Questionnaire-5 <1.5 [Workgroup] or ≤0.75 [JGL/PGAM]); Workgroup and JGL also assessed lung function (change from baseline in trough forced expiratory volume in 1 s of ≥0 [stabilized] or ≥100 mL [optimized]). Results: CR attainability varied on definition and thresholds used. At Week 24 in the CAPTAIN Japanese subpopulation, 34–59% and 18–45% of participants (Workgroup; stabilized and optimized), and 21–34% and 8–24% (JGL; stabilized and optimized) met CR criteria across treatment arms. At Week 52 in the long-term safety study, equivalent figures for CR achievement were 33–60%, 22–45%, 11–28%, and 11–23%. Conclusions: This analysis demonstrates that CR, using different definitions and criteria, is an attainable treatment goal with inhaled therapy in Japanese patients with moderate-to-severe asthma not yet eligible for biologics.Keywords
Funding Information
- GSK (207236/NCT03184987)
- GSK (205715/NCT02924688)
This publication has 17 references indexed in Scilit:
- Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAINAdvances in Therapy, 2025
- Practical Guidelines for Asthma Management (PGAM): Digest editionRespiratory Investigation, 2025
- Clinical remission of mild-to-moderate asthma: Rates, contributing factors, and stabilityJournal of Allergy and Clinical Immunology: Global, 2025
- Pioneering a paradigm shift in asthma management: remission as a treatment goalThe Lancet Respiratory Medicine, 2023
- Asthma control and associated risk factors among adults with current asthma: Findings from 2019 behavioral risk factor surveillance system asthma call-back surveyRespiratory Medicine, 2023
- Are We Ready for Asthma Remission as a Clinical Outcome?Chest, 2023
- Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatmentAnnals of Allergy, Asthma & Immunology, 2023
- Executive summary: Japanese guidelines for adult asthma (JGL) 2021Allergology International, 2023
- Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trialThe Lancet Respiratory Medicine, 2021
- An expert consensus framework for asthma remission as a treatment goalJournal of Allergy and Clinical Immunology, 2020